Specify Company / Ticker to Get the Summary
Dividend History GOSS
Dividend Analytics GOSS
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Gossamer Bio Inc
GOSSGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California. Address: 3115 Merryfield Row, San Diego, CA, United States, 92121
Analytics
WallStreet Target Price
7.61 USDP/E ratio
–Dividend Yield
–Financials GOSS
Results | 2019 | Dynamics |